Polypeptide-corticosteroid conjugates as a topical treatment approach to psoriasis

Dolz-Pérez, Irene; Sallam, Marwa A.; Masiá, Esther; Morelló-Bolumar, Daniel; Caz, M. Dolores Pérez del; Graff, Patrick; Abdelmonsif, Doaa A.; Hedtrich, Sarah; Nebot, Vicent J.; Vicent, María J.

doi:10.1016/j.jconrel.2019.12.016

Cited by 39 publications

(31 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corticosteroids are reported as the most prescribed drugs for this disease, corroborating the Pona et al [32] study. Psoriasis is the second most dermatosis prevalent, the most frequent lesions being desquamative papules/plaques; Corticosteroids are also the most prescribed drugs for psoriasis treatment, which is in accordance with Dolz-Pérez and colleagues [33] study. In this study, seborrheic dermatitis and acne were identified, respectively, as the third and fourth most common dermatoses in Portugal.…”

Section: Discussionsupporting

confidence: 83%

Knowledge and Practices of Community Pharmacists in Topical Dermatological Treatments

Teixeira

Herdeiro

et al. 2021

IJERPH

View full text Add to dashboard Cite

The connection between pharmacists’ knowledge and practice on the provided information to patients about dermatoses and their treatment is insufficiently characterized. Furthermore, pharmacists’ contributions in counselling and in promoting adherence to topical treatment is not fully understood. This study has three main objectives. It aims to identify the knowledge and practices of pharmacists about dermatoses and their treatment, and to compare the perspective of pharmacists with that of patients regarding treatment information, with the future goal of establishing guidelines on the communication of dosage regimen instructions to dermatological patients and promotion of adherence to treatment, filling a gap. A cross-sectional, exploratory, and descriptive study was carried out. Based on experts’ prior knowledge and extensive collected literature information, two questionnaire protocols, one for pharmacists and another one for patients, were designed. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) were carried out in relation to the pharmacists’ questionnaire for instrument validation. The results indicate that knowledge of pharmacists regarding dermatoses and their treatment is considered acceptable. Most of the pharmacists were reported to provide information to patients. Oppositely, patients reported not to have receive it. This is an important issue because pharmacists play a primary role in the management of several diseases. As non-adherence can be triggered by poor understanding of the dosing instructions, pharmacists’ communication practices play an important role in improving this hinderance. Results from this study identified pharmacist–patient communication gaps, so the development of guidelines to improve the transmission of clear dosage regimen instructions and knowledge about patient’s disease are of paramount importance. Training programs for continuous education of pharmacist should be implemented to solve the identified communication problems found in this study.

show abstract

Section: Discussionsupporting

confidence: 83%

Knowledge and Practices of Community Pharmacists in Topical Dermatological Treatments

Teixeira

Herdeiro

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…While this may seem unexpected, this finding agrees well with findings for similar systems. [ 38 ] At pH 7.4 and 5.5, we observed 3% and 2.5% of diDHA release from PGA–diDHA 2.2 and 5% and 4.5% release of diDHA from PGA–diDHA 6.4 at 72 h, respectively. In the case of PGA–diDHA 2.2 at pH 7.4 and 5.5, we observed the sustained release of diDHA over the first 24 h of incubation after an initial “burst” diDHA release, which was then followed by increased release up to 72 h. This plateau may be explained by size, presence of distinct species (aggregates) in solution, or modulated drug exposure.…”

Section: Resultsmentioning

confidence: 78%

Polymer Conjugation of Docosahexaenoic Acid Potentiates Cardioprotective Therapy in Preclinical Models of Myocardial Ischemia/Reperfusion Injury

Tejedor

Dolz-Pérez

Decker

et al. 2021

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

While coronary angioplasty represents an effective treatment option following acute myocardial infarction, the reperfusion of the occluded coronary artery can prompt ischemia–reperfusion (I/R) injury that significantly impacts patient outcomes. As ω‐3 polyunsaturated fatty acids (PUFAs) have proven, yet limited cardioprotective abilities, an optimized polymer‐conjugation approach is reported that improves PUFAs bioavailability to enhance cardioprotection and recovery in animal models of I/R‐induced injury. Poly‐l‐glutamic acid (PGA) conjugation improves the solubility and stability of di‐docosahexaenoic acid (diDHA) under physiological conditions and protects rat neonatal ventricular myocytes from I/R injury by reducing apoptosis, attenuating autophagy, inhibiting reactive oxygen species generation, and restoring mitochondrial membrane potential. Enhanced protective abilities are associated with optimized diDHA loading and evidence is provided for the inherent cardioprotective potential of PGA itself. Pretreatment with PGA–diDHA before reperfusion in a small animal I/R model provides for cardioprotection and limits area at risk (AAR). Furthermore, the preliminary findings suggest that PGA–diDHA administration in a swine I/R model may provide cardioprotection, limit edema and decrease AAR. Overall, the evaluation of PGA–diDHA in relevant preclinical models provides evidence for the potential of polymer‐conjugated PUFAs in the mitigation of I/R injury associated with coronary angioplasty.

show abstract

“…There has been much interest in the polymeric conjugates, particularly natural polymer-based ones, in the recent years 70 . AmB conjugates have been prepared with proteins or polysaccharides to reduce AmB toxicity by attenuating its aggregation state and providing some additional properties as improved penetration through membranes and macrophage uptake.…”

Section: Np-based Dds For Ambmentioning

confidence: 99%

Delivery strategies of amphotericin B for invasive fungal infections

Wang

Mohammad

Fan

et al. 2021

Acta Pharmaceutica Sinica B

Self Cite

View full text Add to dashboard Cite

Invasive fungal infections (IFIs) represent a growing public concern for clinicians to manage in many medical settings, with substantial associated morbidities and mortalities. Among many current therapeutic options for the treatment of IFIs, amphotericin B (AmB) is the most frequently used drug. AmB is considered as a first-line drug in the clinic that has strong antifungal activity and less resistance. In this review, we summarized the most promising research efforts on nanocarriers for AmB delivery and highlighted their efficacy and safety for treating IFIs. We have also discussed the mechanism of actions of AmB, rationale for treating IFIs, and recent advances in formulating AmB for clinical use. Finally, this review discusses some practical considerations and provides recommendations for future studies in applying AmB for combating IFIs.

show abstract

Polypeptide-corticosteroid conjugates as a topical treatment approach to psoriasis

Cited by 39 publications

References 59 publications

Knowledge and Practices of Community Pharmacists in Topical Dermatological Treatments

Knowledge and Practices of Community Pharmacists in Topical Dermatological Treatments

Polymer Conjugation of Docosahexaenoic Acid Potentiates Cardioprotective Therapy in Preclinical Models of Myocardial Ischemia/Reperfusion Injury

Delivery strategies of amphotericin B for invasive fungal infections

Contact Info

Product

Resources

About